Abstract: The disclosure relates, in part, to a method for detecting an analyte in a sample, comprising: contacting a substrate construct with a sample that may comprise the analyte, and using evanescent wave imaging to detect the analyte.

Abstract: The disclosure is directed to a method for nucleic acid sequencing, comprising: using evanescent wave imaging to identify a 3?-unblocked protected nucleotide incorporated into a sequencing primer.

Abstract: The disclosure is directed to a method for nucleic acid sequencing, comprising: contacting a substrate polynucleotide immobilized to a substrate with a protected nucleotide and a sequencing primer in a presence of a polymerase such that the polymerase incorporates the protected nucleotide into the sequencing primer, wherein the protected nucleotide comprises a detectable moiety and a photocleavable terminating moiety; using evanescent wave imaging to identify the protected nucleotide incorporated into the sequencing primer; and using evanescent wave imaging to cleave the photocleavable terminating moiety of the protected nucleotide.

Abstract: The disclosure is directed to (i) controlling a first light source to emit a first light into a substrate on which substrate polynucleotides are immobilized, wherein a plurality of substrate polynucleotides are each annealed to a sequencing primer and bound with a polymerase, wherein the substrate polynucleotides are in a presence of a pool of protected nucleotides, and wherein each protected nucleotide comprises a detectable moiety and a photocleavable terminating moiety; (ii) processing a fluorescence signal to identify protected nucleotides incorporated in the sequencing primers; (iii) controlling a second light source to emit a second light into the substrate to cleave the detectable moieties from the incorporated protected nucleotides; (iv) determining one of both of: a percentage of the sequencing primers that incorporated a protected nucleotide and a percentage of the detectable moieties cleaved from the incorporated protected nucleotides; and (v) modifying one or more parameters of a sequencing primer

Abstract: The disclosure is directed to a compound of formula III: wherein: X is a heteroatom; Base is a nucleobase; R1 and R2 are each independently selected from the group consisting of H, CF3, CN, a C1-C12 straight chain or branched alkyl, a C2-C12 straight chain or branched alkenyl or polyenyl, a C2-C12 straight chain or branched alkynyl or polyalkynyl, a C1-C12 ether, and an aromatic group (e.g., a phenyl, a naphthyl, a pyridine), with the proviso that at least one of R1 and R2 is CF3, CN, a C1-C12 straight chain or branched alkyl, a C2-C12 straight chain or branched alkenyl or polyenyl, a C2-C12 straight chain or branched alkynyl or polyalkynyl, a C1-C12 ether, or an aromatic group (e.g., a phenyl, a naphthyl, a pyridine); R3 is NO2; R4 is H; R5 comprises a C1-C12 alkyne, an amide, and/or an amine; R6 is OMe or S—C6H6; and R7 is H or NO2.

Abstract: The disclosure is directed to an imaging device comprising: a reservoir having an interior lower surface; a substrate arranged below the reservoir, wherein at least a portion of an upper surface of the substrate forms the interior lower surface of the reservoir; a first light source arranged proximate to the substrate and configured to direct light into the substrate; an image sensor arranged below the substrate and configured to receive emission light produced within the reservoir.

Abstract: The disclosure is directed to a method for preparing a sample for evanescent wave imaging, comprising: isothermally amplifying a target nucleic acid present in the sample in a reservoir to produce one or more amplicons, wherein the one or more amplicons are immobilized to a bottom surface of the reservoir; and contacting the one or more amplicons with an aqueous solution comprising sequencing reagents comprising a pool of 3?-unblocked protected nucleotides.

Abstract: A rapid diagnostic test apparatus includes: a housing; a sample chamber movably coupled to the housing; and a housing blister compartment arranged in the housing and configured to rupture when the housing is moved relative to the sample chamber from a first position to a second position. The sample chamber may include a vial portion. A vial blister compartment may seal an opening of the vial portion. The sample chamber may include a tube portion disposed in the housing. The vial portion may extend from the housing. The sample chamber may be rotatably coupled to the housing. The housing blister compartment may rupture when the housing is rotated relative to the sample chamber from the first position to the second position. The housing blister compartment may contain a fluid that may be released into the housing when in the second position.

Abstract: Provided herein, in some embodiments, are rapid diagnostic tests to detect one or more target nucleic acid sequences (e.g., a nucleic acid sequence of one or more pathogens). In some embodiments, the pathogens are viral, bacterial, fungal, parasitic, or protozoan pathogens, such as SARS-CoV-2 or an influenza virus. Further embodiments provide methods of detecting genetic abnormalities. Diagnostic tests comprising a sample-collecting component, one or more reagents (e.g., lysis reagents, nucleic acid amplification reagents), and a detection component (e.g., a component comprising a lateral flow assay strip) are provided.

Abstract: Provided herein, in some embodiments, are rapid diagnostic tests to detect one or more target nucleic acid sequences (e.g., a nucleic acid sequence of one or more pathogens). In some embodiments, the pathogens are viral, bacterial, fungal, parasitic, or protozoan pathogens, such as SARS-CoV-2 or an influenza virus. Further embodiments provide methods of detecting genetic abnormalities. Diagnostic tests comprising a sample-collecting component, one or more reagents (e.g., lysis reagents, nucleic acid amplification reagents), and a detection component (e.g., a component comprising a lateral flow assay strip and/or a colorimetric assay) are provided.

Abstract: Described herein in an embodiment is a diagnostic device for detecting the presence of one or more target nucleic acids (e.g., a nucleic acid of a pathogen, such as SARS-CoV-2 or an influenza virus). In some cases, the diagnostic device comprises a substrate comprising both a reagent delivery region comprising one or more reagents (e.g., one or more nucleic acid amplification reagents) and a lateral flow assay region configured to detect one or more target nucleic acids. The substrate may be removably or permanently coupled to an inner component that is movable relative to an outer component. The diagnostic device may further comprise a sample-collecting component coupled to the outer component and/or the inner component. In some embodiments, the inner component may be moved relative to the outer component in order to sequentially expose the substrate to the collected sample. In some cases, the diagnostic device may be used with a reaction tube comprising one or more liquids (e.g.